Patents by Inventor Laura Iris Ferro

Laura Iris Ferro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF DEFIBROTIDE FOR THE INHIBITION OF HEPARANASE
    Publication number: 20150196580
    Abstract: A study has been carried out to verify the effect of Defibrotide on the activity and expression of Heparanase enzyme on myeloma tumor cells (U266) and human microvascular endothelial cells (HMEC). The study has demonstrated that defibrotide can be effectively used for the manufacture of a medicament for the treatment of diseases which are positively affected by the inhibition of Heparanse and/or by the downregulation of Heparanse gene expression, such as diabetes.
    Type: Application
    Filed: January 20, 2015
    Publication date: July 16, 2015
    Inventors: Cinara ECHART, Laura Iris FERRO, Massimo IACOBELLI
  • FORMULATIONS WITH ANTI-TUMOUR ACTION
    Publication number: 20140005256
    Abstract: Formulations with anti-tumour action containing defibrotide and at least another active ingredient as active agents.
    Type: Application
    Filed: September 6, 2013
    Publication date: January 2, 2014
    Applicant: GENTIUM SPA
    Inventors: Laura Iris FERRO, Massimo IACOBELLI, Paul RICHARDSON
  • Formulations with anti-tumour action
    Patent number: 8551967
    Abstract: The use of defibrotide as an anti-tumor agent, alone or in combination with other active ingredients with anti-tumor action, is described.
    Type: Grant
    Filed: March 2, 2006
    Date of Patent: October 8, 2013
    Assignee: Gentium SpA
    Inventors: Laura Iris Ferro, Massimo Iacobelli, Paul Richardson
  • DNA-based aptamers for human cathepsin G
    Patent number: 7838506
    Abstract: The present research is directed to the identification of non-peptidic inhibitors of cathepsin G characterised by high levels of selectivity and which can be efficaciously used in the treatment and prophylaxis of inflammatory occurrences and procoagulant conditions. The cathepsin G-inhibiting aptamers according to the invention consist of linear DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and being substantially not subjected to undergo efficient base pairing.
    Type: Grant
    Filed: January 17, 2008
    Date of Patent: November 23, 2010
    Assignee: Gentium SpA
    Inventors: Manlio Palumbo, Barbara Gatto, Rodolfo Pescador, Roberto Porta, Laura Iris Ferro
  • Use of sulglicotide for the treatment of mucositis
    Patent number: 7662777
    Abstract: A method for the treatment and/or prevention of mucositis due to an antitumour treatment which comprises the administration of a composition containing suiglicotide to a patient in needs of said antitumour treatment.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: February 16, 2010
    Assignee: Gentium SpA
    Inventors: Massimo Iacobelli, Laura Iris Ferro
  • USE OF DEFIBROTIDE FOR THE INHIBITION OF HEPARANASE
    Publication number: 20090131362
    Abstract: A study has been carried out to verify the effect of Defibrotide on the activity and expression of Heparanase enzyme on myeloma tumor cells (U266) and human microvascular endothelial cells (HMEC). The study has demonstrated that defibrotide can be effectively used for the manufacture of a medicament for the treatment of diseaseses which are positively affected by the inhibition of Heparanse and/or by the downregulation of Heparanse gene expression, such as diabetes.
    Type: Application
    Filed: May 14, 2007
    Publication date: May 21, 2009
    Applicant: Gentium SPA
    Inventors: Cinara Echart, Laura Iris Ferro, Massimo Iacobelli
  • Use of Sulgliocotide for the Treatment of Mucositis
    Publication number: 20080234180
    Abstract: Use of sulgliocotide in the treatment or prevention of mucositis.
    Type: Application
    Filed: May 12, 2005
    Publication date: September 25, 2008
    Applicant: TIUM SPA
    Inventors: Massimo Iacobelli, Laura Iris Ferro
  • Oligodeoxyribonuleotides of 4000-10000 Dalton for Treating
    Publication number: 20080194506
    Abstract: The use of oligodeoxyribonucleotides having a molecular weight of 4000-10000 Dalton as an anti-tumour agent, alone or in combination with other active ingredients with anti-tumour action, is described. The oligotide may be produced by extraction from animal and/or vegetable tissues, in particular, from mammalian organs, or may be produced synthetically. The tumors which can be treated are preferably angiogenesis-dependent tumors, such as multiple myeloma or breast carcinoma.
    Type: Application
    Filed: February 27, 2006
    Publication date: August 14, 2008
    Applicant: Gentium SPA
    Inventors: Massimo Iacobelli, Gunter Eissner, Laura Iris Ferro
  • Defibrotide An/Or Oligodeoxyribonucleotides For Treating Angiogenesis-Dependent Tumors
    Publication number: 20080194507
    Abstract: The use of defibrotide and/or oligodeoxyribonucleotides having a molecular weight of 4000-10000 Dalton as an anti-tumour agent, alone or in combination with other active ingredients with anti-tumour action, is described. The oligotide may be produced by extraction from animal and/or vegetable tissues, in particular, from mammalian organs, or may be produced synthetically. The tumors which can be treated are preferably angiogenesis-dependent tumors, such as multiple myeloma or breast carcinoma.
    Type: Application
    Filed: February 27, 2006
    Publication date: August 14, 2008
    Inventors: Massimo Iacobelli, Gunther Eissner, Laura Iris Ferro
  • DNA-BASED APTAMERS FOR HUMAN CATHEPSIN G
    Publication number: 20080176814
    Abstract: The present research is directed to the identification of non-peptidic inhibitors of cathepsin G characterised by high levels of selectivity and which can be efficaciously used in the treatment and prophylaxis of inflammatory occurrences and procoagulant conditions. The cathepsin G-inhibiting aptamers according to the invention consist of linear DNA or polynucleotide sequences having a chain length of at least 60 nucleotides and being substantially not subjected to undergo efficient base pairing.
    Type: Application
    Filed: January 17, 2008
    Publication date: July 24, 2008
    Applicant: GENTIUM SPA
    Inventors: Manlio PALUMBO, Barbara GATTO, Rodolfo PESCADOR, Roberto PORTA, Laura Iris FERRO